TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29374510

Group type: EXPERIMENTAL
Intervention: Low Protein Diet (5% protein)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Normal Protein Diet (15% protein)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: High Protein Diet (25% protein)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Overfeeding (40% increase in energy intake)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Changes in short-chain fatty acyl-carnitines
Number of subjects: 23
Study: 26666774

Group type: EXPERIMENTAL
Intervention: Nebulized amphotericin B (NAB) plus nebulized budesonide (NEB)
Number of subjects: 21

Group type: COMPARATOR
Intervention: NEB alone
Number of subjects: 21
Study: 28322035

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation program (3 months) including physical training and psycho-educational sessions
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation program (3 months)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 209
Study: 23586456

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment incorporating aspects of imaginal desensitization and motivational interviewing
Number of subjects: 0
Study: 21144705

Group type: EXPERIMENTAL
Intervention: Physiotherapy interventions (various)
Number of subjects: 10025
Study: 19272497

Group type: EXPERIMENTAL
Intervention: EE/DNG
Number of subjects: 1326

Group type: EXPERIMENTAL
Intervention: EE/CPA
Number of subjects: 1326

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1326
Study: 17317858

Group type: EXPERIMENTAL
Intervention: Best available drug treatment (IFN based)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Early allogeneic hematopoietic stem cell transplantation (HSCT)
Number of subjects: 354
Study: 15792016

Group type: EXPERIMENTAL
Intervention: VIBOVITmama supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11574441

Group type: EXPERIMENTAL
Intervention: Fidarestat (1 mg daily for 52 weeks)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study: 9663359

Group type: EXPERIMENTAL
Intervention: Fluticasone 50 micrograms BID
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Fluticasone 100 micrograms BID
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study: 8800732

Group type: EXPERIMENTAL
Intervention: Quadruple therapy plus methotrexate (n = 17)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Quadruple therapy (n = 19)
Number of subjects: 36
Study: 1964678

Group type: EXPERIMENTAL
Intervention: Granisetron 160 micrograms/kg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Granisetron 40 micrograms/kg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Granisetron (40‐240 micrograms/kg over a 24 hour period)
Number of subjects: 56
Study: 6444241

Group type: EXPERIMENTAL
Intervention: Cl2MDP (dichloromethylene diphosphonate) for eight weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo for eight weeks
Number of subjects: 10
Study: 30485665

Group type: EXPERIMENTAL
Intervention: Omaha System-based discharge guidance
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 150
Study: 27760494

Group type: EXPERIMENTAL
Intervention: Intercuspal Position (ICP)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Blocked Occlusion (BO)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Angle-class, midline-displacement, crossbite, or orthodontic therapy
Number of subjects: 87
Study: 25775223

Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 23274597

Group type: EXPERIMENTAL
Intervention: 2.8 mg·kg BM of PSE
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study: 21088211

Group type: EXPERIMENTAL
Intervention: High dietary salt intake (128 mmol sodium/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low dietary salt intake (60‐80 mmol sodium/day)
Number of subjects: 10
Study: 19350123

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 477

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 477

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 477
Study: 17369520

Group type: EXPERIMENTAL
Intervention: Intramuscular electrical stimulation (n = 32)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Hemisling (n = 29)
Number of subjects: 61
Study: 15099280

Group type: EXPERIMENTAL
Intervention: Warfarin for 3 months
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Warfarin for 1 month
Number of subjects: 165
Study: 11283878

Group type: EXPERIMENTAL
Intervention: Focused abdominal sonography for trauma (FAST)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 160
Study: 9087653

Group type: EXPERIMENTAL
Intervention: Esophageal electric stimulation at frequencies ranging from 0.1 to 1 Hz
Number of subjects: 13

Group type: COMPARATOR
Intervention: Baseline respiratory rate
Number of subjects: 13
Study: 7899112

Group type: EXPERIMENTAL
Intervention: Immunization in the ED
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no immunization in the ED)
Number of subjects: 40
Study: 2187174

Group type: EXPERIMENTAL
Intervention: Phenobarbital prophylaxis
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Ventriculomegaly
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Periventricular-intraventricular hemorrhage
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Parenchymal hemorrhage
Number of subjects: 228
Study: 619055

Group type: EXPERIMENTAL
Intervention: Oral antibiotics (ampicillin, cephalexin, cloxacillin, dicloxacillin, penicillin G)
Number of subjects: 21
Study: 30862377

Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty
Number of subjects: 718

Group type: COMPARATOR
Intervention: Eye drops
Number of subjects: 718
Study: 28165771

Group type: EXPERIMENTAL
Intervention: SIPsmartER intervention
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: IVR models
Number of subjects: 155
Study: 25170553

Group type: EXPERIMENTAL
Intervention: Quadrivalent human papillomavirus vaccine (HPV4) before concomitantly administered vaccines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quadrivalent human papillomavirus vaccine (HPV4) after concomitantly administered vaccines
Number of subjects: 0
Study: 24392550

Group type: EXPERIMENTAL
Intervention: Note-taking skills training
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 110
Study: 21806852

Group type: EXPERIMENTAL
Intervention: Antioxidant-rich diet
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Kiwi fruit diet
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study: 19861932

Group type: EXPERIMENTAL
Intervention: Measurement of body mass changes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bioimpedance and urine specific gravity
Number of subjects: 0
Study: 16903595

Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion treatment
Number of subjects: 560

Group type: COMPARATOR
Intervention: Prozac-20
Number of subjects: 560
Study: 15373869

Group type: EXPERIMENTAL
Intervention: Infiltration
Number of subjects: 30

Group type: COMPARATOR
Intervention: Topical spray
Number of subjects: 30
Study: 11282757

Group type: EXPERIMENTAL
Intervention: Exercise (20 min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (8 subjects)
Number of subjects: 14
Study: 9449301

Group type: EXPERIMENTAL
Intervention: Bladder training for 6 weeks
Number of subjects: 123
Study: 7653745

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SC) 10 mg four times daily
Number of subjects: 37

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) 100 micrograms four times daily
Number of subjects: 37
Study: 2892143

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg daily) + Hydrochlorothiazide (50 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg daily) + Atenolol (50 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blockers and Diuretics
Number of subjects: 0
Study: 29631764

Group type: EXPERIMENTAL
Intervention: Skin temperature over myofascial trigger points in the upper trapezius muscle
Number of subjects: 40
Study: 26783268

Group type: EXPERIMENTAL
Intervention: Carbon nanoparticle suspension (CNPS)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 156
Study: 24323568

Group type: EXPERIMENTAL
Intervention: Acute inflammation at baseline biopsy
Number of subjects: 6238

Group type: EXPERIMENTAL
Intervention: Chronic inflammation at baseline biopsy
Number of subjects: 6238

Group type: EXPERIMENTAL
Intervention: Acute inflammation at 4-year biopsy
Number of subjects: 6238
Study: 23849325

Group type: EXPERIMENTAL
Intervention: 60 mg nifedipine and 32 mg candesartan FDC
Number of subjects: 49

Group type: COMPARATOR
Intervention: Loose combination of 60 mg nifedipine GITS and 32 mg candesartan
Number of subjects: 49

Group type: COMPARATOR
Intervention: 60 mg nifedipine GITS alone
Number of subjects: 49

Group type: COMPARATOR
Intervention: 32 mg candesartan alone
Number of subjects: 49
Study: 20004740

Group type: EXPERIMENTAL
Intervention: Adapted physical activity sessions during hospitalization
Number of subjects: 0
Study: 19047883

Group type: EXPERIMENTAL
Intervention: Data-based system (Sabacare Clinical Care Classification System)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Type-in text-based system
Number of subjects: 0
Study: 16724230

Group type: EXPERIMENTAL
Intervention: ADIPOR1 gene variations (specifically SNPs rs10920534, rs22757538, rs1342387)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ADIPOR1 gene variations (specifically SNPs rs10920534, rs12045862, rs7539542)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haplotype analysis with five markers
Number of subjects: 0
Study: 12925476

Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine 0.2 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine 0.3 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine 0.4 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine 0.5 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine (all doses)
Number of subjects: 200
Study: 10814655

Group type: COMPARATOR
Intervention: Simple advice (group A)
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: More active programme (group B)
Number of subjects: 1095
Study: 9007178

Group type: EXPERIMENTAL
Intervention: MCT/LCT emulsion
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: LCT emulsion
Number of subjects: 44

Group type: COMPARATOR
Intervention: Glucose-saline
Number of subjects: 44
Study: 1743661

Group type: EXPERIMENTAL
Intervention: Experimental group (279 patients, 153 enrolled in CPS)
Number of subjects: 1587

Group type: COMPARATOR
Intervention: Control group (143 patients)
Number of subjects: 1587
Study: 6360298

Group type: EXPERIMENTAL
Intervention: Cystoscopy and Otis urethrotomy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Cystoscopy alone
Number of subjects: 64
Study: 31888543

Group type: EXPERIMENTAL
Intervention: Distraction techniques
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study: 28987981

Group type: EXPERIMENTAL
Intervention: Complicated Grief (CG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current major depression (DEPRESSED)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls (CONTROLS)
Number of subjects: 0
Study: 27466239

Group type: EXPERIMENTAL
Intervention: Financial incentives for smoking abstinence (vouchers increasing with duration of abstinence)
Number of subjects: 0

Group type: COMPARATOR
Intervention: €20 vouchers at each visit (control group)
Number of subjects: 0
Study: 25225436

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg once per day
Number of subjects: 940

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 940
Study: 22468423

Group type: EXPERIMENTAL
Intervention: Approach motivation with goal reference line
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avoidance motivation with goal reference line
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic approach motivation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic avoidance motivation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulated approach motivation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulated avoidance motivation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gain-focused health message
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loss-focused health message
Number of subjects: 0
Study: 19718941

Group type: EXPERIMENTAL
Intervention: Spiritually based educational intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-spiritually based educational intervention
Number of subjects: 0
Study: 17617287

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg packet (sachet) formulation
Number of subjects: 96
Study: 15669599

Group type: EXPERIMENTAL
Intervention: Eye contact
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Stare technique (20 to 30 seconds after command)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study: 12533060

Group type: EXPERIMENTAL
Intervention: Trillium-coated Affinity open reservoir oxygenator
Number of subjects: 98

Group type: COMPARATOR
Intervention: Uncoated Affinity open reservoir oxygenator
Number of subjects: 98
Study: 9523865

Group type: EXPERIMENTAL
Intervention: F13 (13 g/l protein)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: F15 (15 g/l protein)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: F18 (18 g/l protein)
Number of subjects: 5

Group type: COMPARATOR
Intervention: B (breast-fed)
Number of subjects: 5

Group type: COMPARATOR
Intervention: M (mixed-fed)
Number of subjects: 5
Study: 7714086

Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH‐a)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Oral contraceptive pills (OCPs)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Combination of OCPs and GnRH‐a
Number of subjects: 33

Group type: COMPARATOR
Intervention: OCPs alone
Number of subjects: 33
Study: 2692963

Group type: EXPERIMENTAL
Intervention: 50 micrograms ethinyl estradiol (EE) and 1.0 mg norethindrone (NE)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: 35 micrograms ethinyl estradiol (EE) and 1.0 mg norethindrone (NE)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: 35 micrograms ethinyl estradiol (EE) and 0.5 mg norethindrone (NE)
Number of subjects: 192
Study: 589167

Group type: EXPERIMENTAL
Intervention: Fenfluramine, 160 mg/day maximum plateau dose
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fenfluramine, <100 ng/ml concentration
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 50
Study: 31291507

Group type: EXPERIMENTAL
Intervention: SystemCHANGE™ intervention
Number of subjects: 89

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 89
Study: 30587959

Group type: EXPERIMENTAL
Intervention: Nebulized glycopyrrolate (GLY) 25 μg BID
Number of subjects: 1294

Group type: EXPERIMENTAL
Intervention: Nebulized glycopyrrolate (GLY) 50 μg BID
Number of subjects: 1294

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1294
Study: 29410921

Group type: EXPERIMENTAL
Intervention: CPAP with SensAwake technology
Number of subjects: 65

Group type: COMPARATOR
Intervention: CPAP without SensAwake technology
Number of subjects: 65
Study: 25779750

Group type: EXPERIMENTAL
Intervention: Apremilast 20 mg twice a day
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice a day
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: MRI substudy (both apremilast doses)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Both apremilast doses
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Overall treatment groups
Number of subjects: 237
Study: 23052714

Group type: COMPARATOR
Intervention: Mitomycin C (MMC)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TAC)
Number of subjects: 64
Study: 22077680

Group type: EXPERIMENTAL
Intervention: LED activation for 40 or 20 seconds (1,200 mW/cm2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Halogen lamp (QTH) activation for 40 seconds (700 mW/cm)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Storage for 24 hours
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Storage for 6 months
Number of subjects: 30
Study: 18847340

Group type: EXPERIMENTAL
Intervention: Peroral nimodipine
Number of subjects: 106

Group type: COMPARATOR
Intervention: Intravenous nimodipine
Number of subjects: 106
Study: 18694222

Group type: EXPERIMENTAL
Intervention: Advanced internet videoconferencing software and improved network connectivity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel combinations of existing open source solutions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simplified installation, configuration, and operation of videoconferencing
Number of subjects: 0
Study: 15541126

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 11358646

Group type: EXPERIMENTAL
Intervention: Estradiol (E(2)) 1 mg/day and 2 mg/day
Number of subjects: 33

Group type: COMPARATOR
Intervention: Estradiol (E(2)) 2 mg/day plus 300 mg/day natural progesterone (P)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Estradiol (E(2)) 2 mg/day plus 5 mg/day medroxyprogesterone acetate (MPA)
Number of subjects: 33
Study: 9625339

Group type: EXPERIMENTAL
Intervention: Caffeine (10 mg/kg then 2.5 mg/kg once daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Theophylline (4 mg/kg then 2 mg/kg twice daily)
Number of subjects: 50
Study: 7908778

Group type: EXPERIMENTAL
Intervention: Azelastine 2 sprays/nostril q24h
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Azelastine 2 sprays/nostril q12h
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Oral chlorpheniramine maleate 12 mg q12h
Number of subjects: 294

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study: 3261158

Group type: EXPERIMENTAL
Intervention: Fiberoptic injection sclerotherapy (FIS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Rigid scope technique (RIS)
Number of subjects: 70
Study: 31219367

Group type: EXPERIMENTAL
Intervention: Haloperidol (HAL; 3 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fluphenazine (FLU; 3 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amphetamine (AMPH; 20 mg)
Number of subjects: 30
Study: 27967270

Group type: EXPERIMENTAL
Intervention: β-alanine supplementation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 26456372

Group type: EXPERIMENTAL
Intervention: Roflumilast 100 μg, 250 μg, or 500 μg once daily
Number of subjects: 3802

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) 400 μg or 500 μg twice daily
Number of subjects: 3802

Group type: COMPARATOR
Intervention: Montelukast 10 mg once daily
Number of subjects: 3802
Study: 22421315

Group type: EXPERIMENTAL
Intervention: Simulations with debriefing and Advanced Cardiac Life Support course
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Simulations with debriefing
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Advanced Cardiac Life Support course
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no additional interventions)
Number of subjects: 14
Study: 21505506

Group type: EXPERIMENTAL
Intervention: Beta-glucan-enriched foods
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rice bran-enriched foods
Number of subjects: 24
Study: 19097918

Group type: EXPERIMENTAL
Intervention: Stent-grafts
Number of subjects: 81

Group type: COMPARATOR
Intervention: Bare stents
Number of subjects: 81
Study: 16269428

Group type: EXPERIMENTAL
Intervention: naproxen 500 mg twice daily
Number of subjects: 511

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 511
Study: 14550680

Group type: EXPERIMENTAL
Intervention: Nefazodone (maximum dose 600 mg/day)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 165
Study: 11108760

Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement (CIM) therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional upper-extremity (UE) therapies
Number of subjects: 20
Study: 8725454

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy followed by surgery (ES + S)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Surgery alone (SA)
Number of subjects: 33
Study: 1305840

Group type: EXPERIMENTAL
Intervention: Paracetamol (with or without codeine)
Number of subjects: 125

Group type: COMPARATOR
Intervention: NSAI (Piroxicam, Indometazine, Ketoprofen, Diclofenac)
Number of subjects: 125
Study: 3987177

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg every 6 hours)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice a day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 29846604

Group type: EXPERIMENTAL
Intervention: 1% transdermal testosterone gel applied daily for 3 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo applied daily for 3 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison between testosterone and placebo
Number of subjects: 0
Study: 26406203

Group type: EXPERIMENTAL
Intervention: Dry needling to the lumbar multifidus muscles using a deep insertion technique with 4 needles (2 on each side of the spine), needles left in situ for 10 minutes
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study: 24131367

Group type: EXPERIMENTAL
Intervention: Sotrastaurin (50 ng/ml)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Neoral (Calcineurin inhibitor)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sotrastaurin
Number of subjects: 21
Study: 23150707

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation with fluorouracil (FU) plus mitomycin (MMC)
Number of subjects: 649

Group type: COMPARATOR
Intervention: Induction plus concurrent fluorouracil (FU) plus cisplatin (CDDP)
Number of subjects: 649
Study: 20694446

Group type: EXPERIMENTAL
Intervention: Tier 1 Program of Project P.A.T.H.S. (experimental group)
Number of subjects: 3170

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3170